CorVel (NASDAQ:CRVL) Posts Quarterly Earnings Results

CorVel (NASDAQ:CRVL) released its quarterly earnings data on Tuesday. The business services provider reported $0.46 earnings per share (EPS) for the quarter, Zacks reports. CorVel had a net margin of 9.64% and a return on equity of 31.73%.

CorVel Stock Performance

CRVL stock opened at $117.58 on Tuesday. The firm has a market cap of $6.00 billion, a price-to-earnings ratio of 75.64 and a beta of 1.16. The firm has a 50-day simple moving average of $123.76 and a two-hundred day simple moving average of $111.79. CorVel has a one year low of $76.20 and a one year high of $127.24.

Insider Activity at CorVel

In other CorVel news, EVP Mark E. Bertels sold 1,050 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $119.12, for a total value of $125,072.50. Following the completion of the sale, the executive vice president now directly owns 2,580 shares in the company, valued at approximately $307,321. This trade represents a 28.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 47.57% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut CorVel from a “buy” rating to a “hold” rating in a report on Friday, January 3rd.

About CorVel

CorVel Corporation provides workers’ compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.